Atherosclerosis
-
Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Load moreSubstantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Load Less
Editor's choice
-
Sven M FrancqueEuropean Cardiology Review 2014;9(1):10–5
Videos
-
29 August 2017
-
28 August 2017
-
18 August 2017
-
Charles Amir German, Michael D ShapiroEuropean Cardiology Review 2020;15:e56.DOI: https://doi.org/10.15420/ecr.2019.18
-
Tanush Gupta, Michael Weinreich, Mark Greenberg, et alInterventional Cardiology Review 2019;14(3):182–9.DOI: https://doi.org/10.15420/icr.2019.17.R1
-
Joost Daemen, Maria Natalia Tovar ForeroInterventional Cardiology Review 2019;14(3):174–81.DOI: https://doi.org/10.15420/icr.2019.18.R1
-
Nobutoyo Masunaga, Shuichi Ura, Mitsuru Ishii, et alEuropean Cardiology Review 2018;13(2):123.DOI: https://doi.org/10.15420/ecr.2018.13.2.PO4
